Tell me everything about organophosphate poisoning Treatment workup diagnosis pathology treatment short term ling term effects physio to pathology medicine
Reading File
Organophosphate poisoning is a medical emergency caused by pesticides and some nerve agents. It produces a cholinergic crisis that can rapidly cause respiratory failure, seizures, cardiac instability, and death. Immediate emergency care and poison-center/toxicology input are needed.
Topic map
-
Physiology and toxic mechanism
- Normal acetylcholine signaling
- Acetylcholinesterase inhibition
- “Aging” of the enzyme-pesticide complex
- Muscarinic, nicotinic, and central nervous system effects
-
Pathology and clinical features
- Cholinergic toxidrome
- Respiratory, neurologic, cardiovascular, gastrointestinal, and eye findings
- Intermediate syndrome and delayed neuropathy
-
Diagnosis and workup
- Exposure history and examination
- Differential diagnosis
- Cholinesterase testing and its limitations
- Blood tests, ECG, imaging, and monitoring
-
Emergency treatment
- Scene safety and decontamination
- Airway, oxygenation, ventilation
- Atropine titration and endpoints
- Oxime treatment such as pralidoxime
- Benzodiazepines for seizures/agitation
- ICU monitoring and complications
-
Short-term effects and prognosis
- Acute respiratory failure, aspiration, arrhythmias, shock
- Intermediate syndrome
- Complications of intensive care and ventilation
-
Long-term effects
- Organophosphate-induced delayed neuropathy
- Neuropsychiatric, cognitive, and motor symptoms
- Rehabilitation and follow-up
High-level overview
Organophosphates inhibit acetylcholinesterase, so acetylcholine accumulates at muscarinic receptors, nicotinic neuromuscular junctions, and in the brain. This causes excessive secretions and bronchospasm, bradycardia or sometimes tachyarrhythmias, vomiting and diarrhea, miosis, muscle fasciculations and weakness, confusion, seizures, and coma. Death is usually from respiratory failure: a mixture of bronchorrhea, bronchospasm, central respiratory depression, and paralysis.
Diagnosis is primarily clinical: a compatible exposure plus a cholinergic toxidrome. Plasma pseudocholinesterase and red-cell acetylcholinesterase can support the diagnosis, but treatment must never wait for results.
Management priorities are personal protection and decontamination, immediate airway and ventilatory support, aggressive atropine to dry dangerous airway secretions and improve ventilation, and early consideration of pralidoxime in significant pesticide exposure. Patients often require intensive-care observation because weakness can recur or worsen after the initial cholinergic phase.
Which section should I cover in full detail first?
- Physiology to pathology
- Diagnosis and workup
- Emergency treatment protocol
- Short-term and long-term effects
- A complete exam-style clinical note, delivered in sections
All of them
Reading File
A full note on all six areas is best delivered as sequential sections rather than a single unsafe-to-skim dump. I can start with the mechanism and acute emergency management, then continue through diagnosis, pathology, and long-term sequelae.
Asking for Preferences
Choose how you want the complete coverage delivered.
Organophosphate poisoning is a medical emergency caused by pesticides and some nerve agents. It produces a cholinergic crisis that can rapidly cause respiratory failure, seizures, cardiac instability, and death. Immediate emergency care and poison-center/toxicology input are needed.
Topic map
-
Physiology and toxic mechanism
- Normal acetylcholine signaling
- Acetylcholinesterase inhibition
- “Aging” of the enzyme-pesticide complex
- Muscarinic, nicotinic, and central nervous system effects
-
Pathology and clinical features
- Cholinergic toxidrome
- Respiratory, neurologic, cardiovascular, gastrointestinal, and eye findings
- Intermediate syndrome and delayed neuropathy
-
Diagnosis and workup
- Exposure history and examination
- Differential diagnosis
- Cholinesterase testing and its limitations
- Blood tests, ECG, imaging, and monitoring
-
Emergency treatment
- Scene safety and decontamination
- Airway, oxygenation, ventilation
- Atropine titration and endpoints
- Oxime treatment such as pralidoxime
- Benzodiazepines for seizures/agitation
- ICU monitoring and complications
-
Short-term effects and prognosis
- Acute respiratory failure, aspiration, arrhythmias, shock
- Intermediate syndrome
- Complications of intensive care and ventilation
-
Long-term effects
- Organophosphate-induced delayed neuropathy
- Neuropsychiatric, cognitive, and motor symptoms
- Rehabilitation and follow-up
High-level overview
Organophosphates inhibit acetylcholinesterase, so acetylcholine accumulates at muscarinic receptors, nicotinic neuromuscular junctions, and in the brain. This causes excessive secretions and bronchospasm, bradycardia or sometimes tachyarrhythmias, vomiting and diarrhea, miosis, muscle fasciculations and weakness, confusion, seizures, and coma. Death is usually from respiratory failure: a mixture of bronchorrhea, bronchospasm, central respiratory depression, and paralysis.
Diagnosis is primarily clinical: a compatible exposure plus a cholinergic toxidrome. Plasma pseudocholinesterase and red-cell acetylcholinesterase can support the diagnosis, but treatment must never wait for results.
Management priorities are personal protection and decontamination, immediate airway and ventilatory support, aggressive atropine to dry dangerous airway secretions and improve ventilation, and early consideration of pralidoxime in significant pesticide exposure. Patients often require intensive-care observation because weakness can recur or worsen after the initial cholinergic phase.
Which section should I cover in full detail first?
- Physiology to pathology
- Diagnosis and workup
- Emergency treatment protocol
- Short-term and long-term effects
- A complete exam-style clinical note, delivered in sectionsA full note on all six areas is best delivered as sequential sections rather than a single unsafe-to-skim dump. I can start with the mechanism and acute emergency management, then continue through diagnosis, pathology, and long-term sequelae.
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
organophosphate poisoning treatment
Searching the Web
organophosphate poisoning clinical guidance atropine pralidoxime WHO
Reading File
Reading File
Reading File
Reading File
Reading Web Page
https://wwwn.cdc.gov/TSp/MMG/MMGDetails.aspx?mmgid=1140&toxi…
Reading File
Reading File
Reading File
Searching Images
diagram organophosphate poisoning acetylcholinesterase inhibition cholinergic toxidrome
Organophosphate poisoning
Organophosphates (OPs) are cholinesterase-inhibiting chemicals used mainly as insecticides. Examples include parathion, malathion, diazinon, chlorpyrifos, acephate, and trichlorfon. Exposure can occur by ingestion, inhalation, ocular contact, or skin absorption. It is a time-critical poisoning emergency, since death is commonly due to respiratory failure.
If this concerns an actual exposure: call emergency services and a poison center now. Do not induce vomiting or enter a contaminated area without appropriate protection.
1. Physiology to pathology
Normal physiology
Acetylcholine (ACh) is released at:
- Parasympathetic postganglionic nerve endings
- Autonomic ganglia
- Neuromuscular junctions
- Sweat glands
- Multiple central nervous system synapses
Normally, acetylcholinesterase (AChE) rapidly hydrolyses ACh and terminates its action.
Core toxic mechanism
OPs phosphorylate and inhibit acetylcholinesterase. ACh then accumulates at muscarinic, nicotinic, and CNS receptors.
- Muscarinic overstimulation: secretions, bronchospasm, miosis, bradycardia, vomiting, diarrhea.
- Nicotinic overstimulation: early fasciculations and hypertension/tachycardia, followed by receptor desensitization, weakness, paralysis, and respiratory-muscle failure.
- CNS effects: anxiety, confusion, seizures, coma, central respiratory depression.
Organophosphate binding becomes increasingly irreversible through “aging.” Once aging occurs, AChE cannot be reactivated by an oxime; recovery depends on synthesis of new enzyme, which may take weeks. This is why early pralidoxime is considered in clinically significant OP poisoning. Tintinalli’s Emergency Medicine, p. 1342.
Why respiratory failure occurs
Respiratory collapse is usually multifactorial:
- Bronchorrhea: massive lower-airway secretions
- Bronchospasm
- Respiratory muscle paralysis
- Central respiratory depression
- Aspiration, pulmonary edema, or pneumonia may worsen gas exchange.
2. Clinical features and pathology
Acute cholinergic syndrome
A practical way to remember the muscarinic effects is DUMBELS/SLUDGE:
- Diarrhea and defecation
- Urination
- Miosis, blurred vision
- Bronchorrhea and bronchospasm
- Emesis
- Lacrimation
- Salivation and sweating
Other important findings:
| System | Findings |
|---|---|
| Eyes | Miosis, blurred vision, lacrimation |
| Airways/lungs | Wheeze, bronchorrhea, hypoxia, respiratory distress |
| Heart/vessels | Often bradycardia and hypotension, but nicotine-receptor effects can produce tachycardia/hypertension |
| GI/GU | Nausea, vomiting, abdominal cramps, diarrhea, urinary incontinence |
| Skeletal muscle | Fasciculations, cramping, weakness, hyporeflexia, paralysis |
| CNS | Headache, agitation, confusion, ataxia, seizures, coma |
| Skin | Diaphoresis; pesticide formulation may cause dermatitis |
The most important bedside danger sign is not miosis. It is wet lungs with inadequate ventilation. Atropine should be titrated to improvement in bronchial secretions and bronchospasm, not normalization of pupils or heart rate. Merck’s professional overview supports this principle.
Pathologic phases
A. Acute cholinergic crisis
Usually begins within minutes to hours. Most symptomatic patients declare themselves within 8 hours, and nearly all do so within 24 hours after an important acute exposure. Tintinalli’s Emergency Medicine, p. 1342.
B. Intermediate syndrome
Occurs after apparent improvement from the acute crisis, generally 1 to 4 days later.
Features:
- Proximal limb and neck-flexor weakness
- Cranial-nerve weakness: dysphagia, dysarthria, facial weakness
- Reduced reflexes
- Respiratory-muscle weakness or paralysis
It may require prolonged ventilation. It is clinically important because recurrence of respiratory failure can occur after the initial secretions seem controlled. Henry’s Clinical Diagnosis and Management by Laboratory Methods, section “Organophosphates and Carbamates.”
C. Organophosphate-induced delayed neuropathy, OPIDN
Usually arises 1 to 3 weeks, sometimes 2 to 5 weeks, after exposure to certain OPs. It results from inhibition and aging of neuropathy target esterase, not simply persistent AChE inhibition.
Typical pattern:
- Burning feet, paresthesia, calf cramps
- Symmetric distal motor weakness, often beginning in legs
- Foot drop, gait difficulty, loss of ankle reflexes
- Sensorimotor axonopathy on nerve-conduction/electromyographic testing
- Severe cases: ascending weakness, spasticity or upper motor neuron findings, functional disability
There is no antidote proven to stop established OPIDN. Rehabilitation is central. Bradley and Daroff’s Neurology in Clinical Practice, section “Organophosphates.”
3. Diagnosis
Diagnosis is primarily clinical. Do not delay treatment to wait for laboratory confirmation.
Exposure history
Ask or obtain:
- Product container, label, trade name, active ingredients, concentration
- Time and route: ingestion, inhalation, dermal, ocular
- Amount potentially involved
- Co-ingestants, especially alcohol, hydrocarbons, solvents, other pesticides
- Occupation: spraying, mixing, field re-entry, agricultural work
- Intentional versus accidental exposure
- Whether other people or responders became symptomatic
The exact product matters because agricultural formulations may contain toxic solvents or surfactants in addition to the OP. Poison-center or medical-toxicology consultation is recommended. Tintinalli’s Emergency Medicine, p. 1342.
Examination
Perform serial assessment of:
- Airway secretions, wheeze, oxygenation, work of breathing
- Mental status and seizures
- Pupils, diaphoresis, bowel sounds
- Bradycardia/hypotension or dysrhythmia
- Fasciculations, muscle power, reflexes, bulbar weakness
- Skin/eye contamination
Laboratory workup
Obtain investigations based on severity, but do not postpone antidotes:
- Bedside glucose
- Continuous ECG and pulse oximetry
- Blood gas or venous gas, lactate if ill
- CBC, electrolytes, renal function, liver tests
- Creatine kinase if seizures, prolonged immobilization, or rhabdomyolysis is possible
- Chest radiograph if hypoxemia, aspiration, pulmonary edema, or pneumonia is suspected
- Pregnancy test when applicable
- Toxicology testing when it affects management
Cholinesterase tests
-
Red-blood-cell acetylcholinesterase (RBC AChE, “true” cholinesterase)
- More closely reflects synaptic AChE inhibition
- More specific and may correlate with severity
- Useful for confirmation and trend monitoring if available promptly
-
Plasma butyrylcholinesterase or pseudocholinesterase
- More readily available in some settings and may be sensitive to exposure
- Less specific and may be low due to liver disease, malnutrition, genetic variants, pregnancy, or other conditions
Neither test should override the clinical picture. A patient with bronchorrhea and weakness needs treatment even before results return. Henry’s Clinical Diagnosis and Management by Laboratory Methods, section “Organophosphates and Carbamates.”
Differential diagnosis
- Carbamate poisoning: same cholinergic toxidrome but inhibition is generally reversible and shorter-lived
- Nicotinic mushroom poisoning
- Nerve-agent exposure
- Cholinergic medication overdose: physostigmine, pyridostigmine, donepezil
- Opioid poisoning: miosis and reduced consciousness, but typically dry lungs and absent cholinergic GI/secretory syndrome
- Clonidine toxicity
- Sepsis, asthma/COPD exacerbation, pulmonary edema
- Botulism or myasthenic crisis: weakness but typically not bronchorrhea, miosis, diarrhea, and diaphoresis
4. Emergency treatment
Treatment should occur in an emergency department or ICU, with a poison center or medical toxicologist involved.
A. Protect staff and prevent secondary contamination
- Use gloves, gown, eye protection, and suitable respiratory protection if contamination is significant.
- Remove clothing and double-bag it.
- Wash skin and hair thoroughly with soap and water.
- Irrigate eyes copiously if exposed.
- Do not allow contaminated clothing, vomitus, or secretions to expose staff or family.
The CDC emphasizes decontamination, cardiopulmonary support, atropine, and pralidoxime for parathion and related OP poisoning. CDC/ATSDR medical guidance
B. ABCs: airway, breathing, circulation
-
Airway
- Suction secretions aggressively.
- Early intubation is often safer when there is declining consciousness, persistent hypoxia, major secretions, respiratory fatigue, severe bronchospasm, or neuromuscular weakness.
-
Breathing
- High-flow oxygen and assisted ventilation as needed.
- Mechanical ventilation may be required for acute poisoning or intermediate syndrome.
-
Circulation
- IV access, cardiac monitoring, fluid resuscitation if hypotensive.
- Treat persistent shock with vasopressors under critical-care guidance.
Avoid succinylcholine if possible because cholinesterase inhibition can greatly prolong paralysis. Use a nondepolarizing paralytic agent if intubation requires neuromuscular blockade.
C. Atropine: first-line antidote for life-threatening muscarinic toxicity
What it treats: bronchorrhea, bronchospasm, bradycardia, and muscarinic secretions.
What it does not reliably treat: muscle weakness or nicotinic paralysis.
A common adult approach is:
- Start atropine 1 to 3 mg IV in a significantly symptomatic adult.
- Reassess within about 3 to 5 minutes.
- Double the dose repeatedly until airway secretions markedly diminish and ventilation/oxygenation improve.
- Once atropinized, continue an infusion or repeated boluses, titrated to recurrent bronchorrhea or bronchospasm.
Pediatric initial dosing is commonly 0.05 mg/kg IV, followed by rapid titration under specialist guidance. Severe poisoning can require very large cumulative quantities. Merck’s treatment guidance
Clinical endpoints of atropinization
- Chest becomes dry or substantially less wet on auscultation
- Bronchial secretions manageable with suctioning
- Improved oxygenation and ventilation
- Reduced bronchospasm and work of breathing
- Adequate blood pressure/perfusion
Do not use pupil size, tachycardia, or dry mouth alone as endpoints. A tachycardic patient may still require more atropine if they have significant bronchorrhea.
Possible atropine excess: delirium, agitation, hyperthermia, ileus, urinary retention, absent bowel sounds, marked tachycardia. Differentiate this from ongoing poisoning, which tends to produce wet secretions and bronchospasm.
D. Pralidoxime, 2-PAM
Role: reactivates phosphorylated AChE before aging and is intended especially for nicotinic effects such as fasciculations, weakness, and respiratory-muscle paralysis. Give after initial atropine and do not delay airway support.
Common hospital dosing ranges:
- Adults: 1 to 2 g IV over 15 to 30 minutes, then repeat doses or continuous infusion according to the local toxicology protocol.
- Children: commonly 20 to 40 mg/kg IV over 15 to 30 minutes, followed by specialist-directed repeat dosing or infusion.
It should be administered as early as possible. The CDC/ATSDR guidance notes diminishing benefit after about 24 to 36 hours, though timing depends on the agent and clinical course.
Evidence caveat: atropine and airway support are universally accepted. The outcome benefit and ideal dose/duration of oximes have varied across trials, partly because OP compounds, formulations, delays to care, and treatment protocols differ. A recent umbrella review of systematic reviews and a 2025 meta-analysis underline ongoing uncertainty about adjunctive therapies. This should not be interpreted as a reason to withhold pralidoxime in a serious suspected OP exposure when toxicology guidance supports it.
E. Seizures, agitation, and CNS toxicity
- Treat seizures with a benzodiazepine, such as diazepam or midazolam, following emergency protocols.
- Correct hypoxia, hypoglycemia, and hyperthermia.
- Continuous monitoring is needed after seizures or coma.
F. Gastrointestinal decontamination
- Activated charcoal may be considered for a recent, potentially toxic ingestion only after the airway is protected and after poison-center/toxicology advice.
- Gastric lavage is not routine and is only considered in very selected life-threatening ingestions with a protected airway.
- Never induce vomiting.
G. Therapies generally not useful
- Hemodialysis and other enhanced-elimination procedures do not remove OPs effectively and have no routine role. Rosen’s Emergency Medicine, section “Enhanced Elimination.”
- Do not rely on antihistamines, bronchodilators, or antibiotics as substitutes for atropine and ventilatory management. Bronchodilators may be an adjunct for persistent bronchospasm.
- Avoid routine use of beta-blockers in unstable severe poisoning unless guided by a specialist.
5. Short-term complications
Monitor in ICU or a high-dependency setting if there are significant symptoms, large exposure, need for atropine infusion, weakness, or respiratory involvement.
Potential acute complications include:
- Hypoxemic or hypercapnic respiratory failure
- Aspiration pneumonitis/pneumonia
- Noncardiogenic pulmonary edema
- Seizures and coma
- Bradyarrhythmias, tachyarrhythmias, QT abnormalities
- Hypotension/shock
- Rhabdomyolysis and acute kidney injury
- Pancreatitis, reported in significant OP poisoning
- Recurrence of secretions after premature atropine reduction
- Intermediate syndrome and delayed respiratory weakness
Observation duration must reflect the agent, formulation, exposure route, symptoms, cholinesterase activity if available, and need for antidotes. A large ingestion or persistent symptoms requires prolonged monitored care.
6. Long-term effects and follow-up
After recovery from acute toxicity
Follow up for:
- Residual weakness, exercise intolerance, dysphagia, dyspnea
- Neuropathic symptoms, gait impairment, foot drop
- Cognitive symptoms: poor attention, memory difficulties
- Mood symptoms, sleep disturbance, anxiety, depression, post-traumatic stress
- Suicide-risk assessment and mental-health care after deliberate ingestion
- Occupational assessment and prevention of re-exposure
OPIDN treatment and rehabilitation
There is no established antidote for established delayed neuropathy. Management includes:
- Neurology referral
- Nerve-conduction studies/EMG if weakness or neuropathy persists
- Physiotherapy, occupational therapy, gait and fall-risk assessment
- Orthoses for foot drop when required
- Neuropathic-pain treatment when indicated
- Vocational and workplace-exposure assessment
Recovery can be prolonged and may be incomplete, particularly with severe axonal injury. Bradley and Daroff’s Neurology in Clinical Practice, section “Organophosphates.”
High-yield exam summary
- Mechanism: irreversible AChE inhibition by phosphorylation, causing ACh accumulation.
- Toxidrome: “wet” patient with miosis, salivation, lacrimation, bronchorrhea, bronchospasm, diarrhea, urination, bradycardia, fasciculations, weakness, seizures.
- Main cause of death: respiratory failure from secretions, bronchospasm, CNS depression, and muscle paralysis.
- Diagnosis: clinical exposure plus cholinergic toxidrome; RBC AChE supports diagnosis but do not wait for it.
- First priorities: rescuer protection, decontamination, suction, oxygen, ventilation, early intubation when indicated.
- Atropine: titrate rapidly to dry lungs/improved ventilation, not pupil size.
- Pralidoxime: give early after atropine for meaningful suspected OP toxicity, especially weakness/fasciculations.
- Seizures: benzodiazepines.
- Delayed complications: intermediate syndrome at 1 to 4 days, OPIDN at roughly 1 to 3 weeks.
Create a one-page emergency treatment algorithm
Reading File
Generating Image
One-page clinical emergency treatment algorithm for suspected organophosphate poisoning. Include a prominent warning: Medical emergency - follow local toxicology protocol and call poison center. Use a readable flowchart that covers: PPE and decontamination; ABC resuscitation with suction, oxygen, early airway control and avoid succinylcholine; atropine IV titration for bronchorrhea/bronchospasm with endpoint of dry lungs and adequate ventilation rather than pupil size; pralidoxime after atropine for significant exposure and neuromuscular toxicity; benzodiazepine for seizures; monitoring, ICU admission criteria, and intermediate syndrome surveillance. Include adult and pediatric initial doses consistent with standard guidance. Make all text legible.
Searching the Web
CDC ATSDR organophosphate poisoning emergency atropine pralidoxime medical management guidelines
Searching PubMed
organophosphate poisoning treatment
Suspected Organophosphate Poisoning: Emergency Treatment Algorithm
Medical emergency. Use local toxicology/poison-center and critical-care protocols. Treat the patient, do not wait for cholinesterase results.
Key safety notes
- Atropine endpoint: clear/drying airway secretions, reduced bronchospasm, and adequate oxygenation/ventilation. Do not titrate to pupil size or heart rate alone.
- Pralidoxime: administer early after atropine for significant suspected OP exposure, particularly with fasciculations, weakness, or respiratory-muscle involvement. Dosing and infusion protocols differ by region and agent.
- Airway: suction aggressively; intubate early for hypoxia, failing ventilation, depressed consciousness, severe bronchorrhea, or weakness. Avoid succinylcholine where feasible because paralysis may be prolonged.
- Monitoring: observe closely for recurrent cholinergic toxicity and intermediate syndrome, which may cause delayed proximal, cranial, and respiratory muscle weakness over the next 1 to 4 days.
The CDC/ATSDR guidance emphasizes decontamination, cardiopulmonary support, atropine, and early pralidoxime. A recent systematic umbrella review notes that evidence for adjunctive interventions varies, but airway support and atropine remain the immediate priorities.
This is a shared conversation. Sign in to Orris to start your own chat.